Literature DB >> 12562450

Cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study.

E Cheong1, L Igali, I Harvey, M Mole, E Lund, I T Johnson, M Rhodes.   

Abstract

BACKGROUND: The incidence of Barrett's oesophageal adenocarcinoma is increasing more rapidly than any other malignancy in industrialized countries. Cyclo-oxygenase-2 appears to play an important role in gastrointestinal carcinogenesis. Previous studies on cyclo-oxygenase-2 expression in Barrett's oesophageal carcinogenesis have utilized tissue samples obtained from different patients. We sought a definitive comparison of cyclo-oxygenase-2 expression in the sequence of Barrett's metaplasia-dysplasia-adenocarcinoma within the same patients.
METHODS: Paraffin-embedded oesophago-gastrectomy specimens from 20 patients, containing successive stages of Barrett's metaplasia, high-grade dysplasia and adenocarcinoma, were analysed for cyclo-oxygenase-2 expression by immunohistochemistry.
RESULTS: Cyclo-oxygenase-2 was constitutively expressed in the basal layers of cells in the adjacent normal squamous oesophageal epithelium, but a higher cyclo-oxygenase-2 expression was observed in Barrett's metaplasia. A further increase in cyclo-oxygenase-2 expression was detected in high-grade dysplasia, but cyclo-oxygenase-2 was decreased in adenocarcinoma tissue, regardless of its stage or level of differentiation.
CONCLUSIONS: Cyclo-oxygenase-2 expression is progressively increased when squamous oesophageal epithelium develops into Barrett's metaplastic epithelium and then into high-grade dysplasia, but appears to decrease when adenocarcinoma develops. These findings may be significant for an effective chemo-prevention strategy with selective cyclo-oxygenase-2 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562450     DOI: 10.1046/j.1365-2036.2003.01432.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  4 in total

1.  Reduced Risk of Barrett's Esophagus in Statin Users: Case-Control Study and Meta-Analysis.

Authors:  Ian L P Beales; Leanne Dearman; Inna Vardi; Yoon Loke
Journal:  Dig Dis Sci       Date:  2015-09-19       Impact factor: 3.199

2.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

3.  Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma.

Authors:  Hidekazu Kuramochi; Daniel Vallböhmer; Kazumi Uchida; Sylke Schneider; Nahid Hamoui; Daisuke Shimizu; Parakrama T Chandrasoma; Tom R DeMeester; Kathleen D Danenberg; Peter V Danenberg; Jeffrey H Peters
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

4.  Barrett's oesophagus and adenocarcinoma.

Authors:  Christine P J Caygill; Anthony Watson; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  World J Surg Oncol       Date:  2004-05-07       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.